Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHR-700 gel for reducing mammographic breast density in women with dense breasts
2017-002906-10Phase 3Completed
- Sponsor
- BHR Pharmaceuticals
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast density comparing Afimoxifene gel with Placebo gel (2 arms). Primary endpoint: Percentage reduction in mammographic breast tissue density. Started Oct 2017; status: completed.
02
Drugs
afimoxifene
03
Conditions
breast density
Beyond the preview
Go deeper on 2017-002906-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002906-10.